

## QVance AB Announces Nordic Partnership with bioMérieux

QVance AB, Huddinge, Sweden has today announced it has entered into a partnership with bioMérieux Sweden AB, aimed at enhancing the quality analytics offerings in microbiology and mycoplasma testing for cell and gene therapy product development and release.

bioMérieux, a world leader in the field of *in vitro* diagnostics, pioneer, develop and produce high quality diagnostic solutions to improve public health worldwide. This collaboration will leverage the strengths of both companies to offer innovative solutions and support the advanced therapy community in the Nordics. QVance, in addition to offering bioMérieux's testing solutions, will offer an opportunity for customers to visit QVance's site in Stockholm and see firsthand bioMérieux's technology. Together, the companies will support the development of rapid and compliant quality control testing methods for advanced therapies in the Nordics.

"The partnership with bioMérieux represents a significant step forward in the establishment of QVance. Collaboration with a global leader such as bioMérieux in our startup phase highlights the clear need for QC analytic provision in the Nordics for the advanced therapy sector, and we are happy to be at the forefront of this development," said Lindsay Davies, CSO of QVance's parent company NextCell Pharma AB and co-founder of QVance.

The partnership is expected to expand QVance's service offerings as well as provide education and support with joint webinars and communications to advanced therapy companies in the Nordics. Both companies are committed to maintaining their high standards of quality and innovation as they work together to achieve mutual goals.

"Our ambition is to be the partner of choice for smart quality control of cell and gene therapy manufacturers", says David Bates, Business Development Manager for Cell & Gene Therapies at bioMérieux. "We are excited about this collaboration with QVance to further support this critical area of modern healthcare and contribute to bringing those advanced therapies to the patients faster."

QVance and bioMérieux will begin implementing joint initiatives immediately, with the launch of QVance at ATMP Sweden in Malmö on November 25<sup>th</sup> 2024.

For more information about the partnership and future developments, please contact:

Lindsay Davies

QVance AB

Email: [info@qvance.se](mailto:info@qvance.se)

Website: [www.qvance.se](http://www.qvance.se)

LinkedIn <https://www.linkedin.com/company/qvance/>

**QVance AB is the daughter company of NextCell Pharma AB**

**For more information regarding NextCell Pharma please contact**

**Mathias Svahn, CEO**

**Patrik Fagerholm, CFO**

**Tel: +46 8 735 55 95**

**E-mail: [info@nextcellpharma.com](mailto:info@nextcellpharma.com)**

**Website: [www.nextcellpharma.com](http://www.nextcellpharma.com)**

**LinkedIn: <https://www.linkedin.com/NextCell-Pharma>**

**Twitter: <https://twitter.com/NextCellPharma>**

**Certified Adviser**

**FNCA Sweden AB is assigned as Certified Adviser.**

**About QVance AB**

**QVance is a quality analytics service provider for advanced therapies. The company's vision is to be a one-stop analytics service supporting customers throughout development and drug product lifecycle.**